<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To date, six classes of oral medication have been approved by the U.S </plain></SENT>
<SENT sid="1" pm="."><plain>Food and Drug Administration for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and several new agents are in the pipeline </plain></SENT>
<SENT sid="2" pm="."><plain>In 2009, the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association and the European Association for the Study of <z:mp ids='MP_0002055'>Diabetes</z:mp> developed a consensus statement regarding the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, citing lifestyle modification and <z:chebi fb="0" ids="6801">metformin</z:chebi> as the preferred first line therapies </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to the currently available drugs, several new agents have recently been introduced or are in the development pipeline </plain></SENT>
<SENT sid="4" pm="."><plain>Incretin therapies include both glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors </plain></SENT>
<SENT sid="5" pm="."><plain>Non-incretin beta cell stimulants still in development include glucokinase activators, G-protein-coupled receptors, and anti-inflammatory and anti-oxidant therapies </plain></SENT>
<SENT sid="6" pm="."><plain>Additional agents that target <z:chebi fb="105" ids="17234">glucose</z:chebi> synthesis include <z:chebi fb="105" ids="17234">glucose</z:chebi>-6-phosphatase and <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase </plain></SENT>
<SENT sid="7" pm="."><plain>Other new agents target <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, which is often the first clinical condition that presents in patients at risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, for <z:mp ids='MP_0001261'>obese</z:mp> patients who are unable to lose weight through diet and exercise, <z:hpo ids='HP_0001824'>weight-loss</z:hpo> surgery is an option that should be discussed with their physicians </plain></SENT>
<SENT sid="9" pm="."><plain>This CME multimedia activity, which is part of a 2-part multimedia activity on the management and treatment of <z:mp ids='MP_0002055'>diabetes</z:mp>, contains a video presentation and is available through the website of The American Journal of Medicine at http://amjmed.com/content/multimedia </plain></SENT>
<SENT sid="10" pm="."><plain>Click on "Management of Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp>: New and Future Developments in Treatment" to access this part of this multimedia program </plain></SENT>
</text></document>